about
Fighting Cancer with Mathematics and Viruses.Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most EffectiveTumour-inducing viruses.Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Designing and building oncolytic viruses.Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.Advances in the mechanisms of action of cancer-targeting oncolytic viruses.Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.Designer Oncolytic Adenovirus: Coming of Age.White paper on microbial anti-cancer therapy and prevention
P2860
Q38612646-B09AFFAC-8CC7-4BD6-9BFF-EC8A858D67C2Q38685020-0E5369DE-9E4C-4AEE-B637-4D35F4C571BCQ38977066-636C1559-F4FD-4E6F-8AAA-7606B50ED4B5Q39359422-EBB5774C-4DA5-4F1D-BFE2-129CEB27328DQ40068135-E0D63AA4-5769-477E-9E22-9691223DE861Q40192795-67A851F3-B91D-4DB3-8FAD-F5B6C911E566Q45324726-80B1BF98-6774-42AF-89AC-D8D7008302D8Q45324769-DC0D5F3E-B554-42D0-8E72-8A3D5A50E26CQ47547386-83145E55-5A58-475B-AEBF-FC02DFC2C6C0Q47559036-DCB45DB7-8D47-4C3E-8B4F-653928993BACQ49787495-F34DD51C-5A2E-4AEC-ABFA-FF9206600A92Q50128059-83AA8DA2-9462-4AF0-A671-51993AF170F9Q52645848-B8383078-F3F3-47CD-99C8-66BCD0B3FA71Q52655195-1E0B1BE7-8E0B-4777-B594-CCA85D158F40Q54213228-46EE02DC-7466-4A0C-8B57-FCA482A43AD2Q55053341-42D1B6AF-92EB-41A0-9308-E181DAFBD33DQ55467684-94F1C49C-FECA-4BA1-80DD-39D7106186C0Q56898750-FD3482AE-4833-41F7-82A6-7C630AA3A89C
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Oncolytic Viruses: Therapeutics With an Identity Crisis
@ast
Oncolytic Viruses: Therapeutics With an Identity Crisis
@en
Oncolytic Viruses: Therapeutics With an Identity Crisis
@nl
type
label
Oncolytic Viruses: Therapeutics With an Identity Crisis
@ast
Oncolytic Viruses: Therapeutics With an Identity Crisis
@en
Oncolytic Viruses: Therapeutics With an Identity Crisis
@nl
prefLabel
Oncolytic Viruses: Therapeutics With an Identity Crisis
@ast
Oncolytic Viruses: Therapeutics With an Identity Crisis
@en
Oncolytic Viruses: Therapeutics With an Identity Crisis
@nl
P2860
P921
P3181
P1433
P1476
Oncolytic Viruses: Therapeutics With an Identity Crisis
@en
P2093
Brian D Lichty
Caroline J Breitbach
P2860
P3181
P356
10.1016/J.EBIOM.2016.06.046
P407
P50
P577
2016-07-01T00:00:00Z